Advertisement
Trends in Pharmacological Sciences
This journal offers authors two options (open access or subscription) to publish research

Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future

  • Zak M. Whiting
    Affiliations
    Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

    Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Search for articles by this author
  • Jiazhen Yin
    Affiliations
    Department of Chemistry, Division of Sciences, University of Otago, Dunedin, New Zealand
    Search for articles by this author
  • Sara M. de la Harpe
    Affiliations
    Department of Chemistry, Division of Sciences, University of Otago, Dunedin, New Zealand
    Search for articles by this author
  • Andrea J. Vernall
    Affiliations
    Department of Chemistry, Division of Sciences, University of Otago, Dunedin, New Zealand

    Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand
    Search for articles by this author
  • Natasha L. Grimsey
    Correspondence
    Correspondence:
    Affiliations
    Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

    Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

    Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand
    Search for articles by this author

      Highlights

      • Cannabinoid Receptor 2 (CB2) is a promising therapeutic target, particularly for inflammatory disorders and pain; however, clinical trials to date have been unsuccessful.
      • Medicinal chemistry efforts have produced selective ligands with a wide range of core scaffolds. Optimisation for drug-like properties and oral administration has been demonstrated to be feasible, but few such compounds have been tested clinically to date.
      • Recent crystal and cryo-EM structures are expected to facilitate rational ligand development and further optimisation.
      • Although CB2 ligands can produce functional selectivity (bias) of signalling responses, few new classes of ligand have been studied in this context. The physiological relevance of CB2 signalling bias, and subcellular spatial organisation of CB2 signalling, remain to be elucidated.
      Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised, therapeutic potential. Promising preclinical data supports the applicability of CB2 activation in autoimmune and inflammatory diseases, pain, neurodegeneration, and osteoporosis. A diverse pharmacopoeia of cannabinoid ligands is available, which has led to considerable advancements in the understanding of CB2 function and extensive preclinical evaluation. However, until recently, most CB2 ligands were highly lipophilic and as such not optimal for clinical application due to unfavourable physicochemical properties. A number of strategies have been applied to develop CB2 ligands to achieve closer to ‘drug-like’ properties and a few such compounds have now undergone clinical trial. We review the current state of CB2 ligand development and progress in optimising physicochemical properties, understanding advanced molecular pharmacology such as functional selectivity, and clinical evaluation of CB2-targeting compounds.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access

      Read-It-Now

      Purchase access to all full-text HTML articles for 6 or 36 hr at a low cost. Click here to explore this opportunity.

      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Trends in Pharmacological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Young A.P.
        • Denovan-Wright E.M.
        The dynamic role of microglia and the endocannabinoid system in neuroinflammation.
        Front. Pharmacol. 2022; 12806417
        • Turcotte C.
        • et al.
        The CB2 receptor and its role as a regulator of inflammation.
        Cell. Mol. Life Sci. 2016; 73: 4449-4470
        • Cassano T.
        • et al.
        Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target.
        Front. Neurosci. 2017; 11: 30
        • Fulmer M.L.
        • Thewke D.P.
        The endocannabinoid system and heart disease: the role of cannabinoid receptor type 2.
        Cardiovasc. Hematol. Disord. Drug Targets. 2018; 18: 34-51
        • Kolb B.
        • et al.
        The endocannabinoid system and stroke: a focused review.
        Brain Circ. 2019; 5: 1-7
        • Shang Y.
        • Tang Y.
        The central cannabinoid receptor type-2 (CB2) and chronic pain.
        Int. J. Neurosci. 2017; 127: 812-823
        • Rossi F.
        • et al.
        The endocannabinoid/endovanilloid system in bone: from osteoporosis to osteosarcoma.
        Int. J. Mol. Sci. 2019; 20: 1919
        • Kumawat V.S.
        • Kaur G.
        Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.
        Eur. J. Pharmacol. 2019; 862172628
        • Rossi F.
        • et al.
        Role of cannabinoids in obesity.
        Int. J. Mol. Sci. 2018; 19: 2690
        • Laezza C.
        • et al.
        The endocannabinoid system: a target for cancer treatment.
        Int. J. Mol. Sci. 2020; 21: 747
        • Zhou L.L.
        • et al.
        Targeted inhibition of the type 2 cannabinoid receptor is a novel approach to reduce renal fibrosis.
        Kidney Int. 2018; 94: 756-772
        • Lunn C.A.
        • et al.
        Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.
        Br. J. Pharmacol. 2008; 153: 226-239
        • Alghamdi S.S.
        • et al.
        Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
        Bioorg. Med. Chem. 2021; 33116035
        • Gareau Y.
        • et al.
        Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors.
        Bioorg. Med. Chem. Lett. 1996; 6: 189-194
        • Hanus L.
        • et al.
        HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor.
        Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 14228-14233
        • Huffman J.W.
        • et al.
        3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor.
        Bioorg. Med. Chem. 1999; 7: 2905-2914
        • Compton D.R.
        • et al.
        Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.
        J. Pharmacol. Exp. Ther. 1992; 263: 1118
        • Showalter V.M.
        • et al.
        Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
        J. Pharmacol. Exp. Ther. 1996; 278: 989-999
        • Rinaldi-Carmona M.
        • et al.
        SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
        J. Pharmacol. Exp. Ther. 1998; 284: 644-650
        • Li X.
        • et al.
        Crystal structure of the human cannabinoid receptor CB2.
        Cell. 2019; 176: 459-467
        • Ross R.A.
        • et al.
        Agonist inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630.
        Br. J. Pharmacol. 1999; 126: 665-672
        • Bolognini D.
        • et al.
        AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.
        Br. J. Pharmacol. 2012; 165: 2561-2574
        • Cooper A.G.
        • et al.
        Alkyl indole-based cannabinoid type 2 receptor tools: exploration of linker and fluorophore attachment.
        Eur. J. Med. Chem. 2018; 145: 770-789
        • Pasquini S.
        • et al.
        Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo.
        J. Med. Chem. 2008; 51: 5075-5084
        • Mugnaini C.
        • et al.
        Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach.
        ChemMedChem. 2012; 7: 920-934
        • Cheng Y.
        • et al.
        Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
        J. Med. Chem. 2008; 51: 5019-5034
        • Yao B.B.
        • et al.
        Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
        J. Pharmacol. Exp. Ther. 2009; 328: 141-151
        • Morales P.
        • et al.
        Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis.
        J. Med. Chem. 2016; 59: 6753-6771
        • Singh S.
        • et al.
        Chromenopyrazole-based high affinity, selective fluorescent ligands for cannabinoid type 2 receptor.
        ACS Med. Chem. Lett. 2019; 10: 209-214
        • Mugnaini C.
        • et al.
        Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease.
        Eur. J. Med. Chem. 2019; 161: 239-251
        • Scott C.E.
        • et al.
        Identification and biochemical analyses of selective CB2 agonists.
        Eur. J. Pharmacol. 2019; 854: 1-8
        • Soethoudt M.
        • et al.
        Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity.
        Nat. Commun. 2017; 8: 13958
        • Yukawa T.
        • Naven R.
        Utility of physicochemical properties for the prediction of toxicological outcomes: Takeda perspective.
        ACS Med. Chem. Lett. 2020; 11: 203-209
        • Young R.J.
        • Leeson P.D.
        Mapping the efficiency and physicochemical trajectories of successful optimizations.
        J. Med. Chem. 2018; 61: 6421-6467
        • Grotenhermen F.
        Clinical pharmacokinetics of cannabinoids.
        J. Cannabis Ther. 2003; 3: 3-51
        • Schnider P.
        Overview of strategies for solving ADMET challenges.
        in: Schnider P. The Medicinal Chemist's Guide to Solving ADMET Challenges. Vol. 79. Royal Society of Chemistry, 2021: 1-15
        • Lipinski C.
        Drug solubility in water and dimethylsulfoxide.
        in: Mannhold R. Molecular Drug Properties: Measurement and Prediction. Methods and Principles in Medicinal Chemistry. Wiley, 2007: 255-282
        • Brailoiu G.C.
        • et al.
        Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors.
        Biochemistry. 2014; 53: 4990-4999
        • Ohta H.
        • et al.
        Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
        Bioorg. Med. Chem. 2008; 16: 1111-1124
        • Blaazer A.R.
        • et al.
        Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure–activity relationships, physicochemical properties and biological activity.
        Eur. J. Med. Chem. 2011; 46: 5086-5098
        • Odan M.
        • et al.
        CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: reduction of CNS side effects by introducing polar functional groups.
        Bioorg. Med. Chem. Lett. 2012; 22: 2894-2897
        • Haruna T.
        • et al.
        The inhibitory effect of S-777469, a cannabinoid type 2 receptor agonist, on skin inflammation in mice.
        Pharmacology. 2017; 99: 259-267
        • Sellitto I.
        • et al.
        Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability.
        Bioorg. Med. Chem. Lett. 2010; 20: 387-391
        • Iwata Y.
        • et al.
        Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome.
        Bioorg. Med. Chem. Lett. 2015; 25: 236-240
        • van der Stelt M.
        • et al.
        Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists.
        J. Med. Chem. 2011; 54: 7350-7362
        • Mukhopadhyay P.
        • et al.
        The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity.
        Br. J. Pharmacol. 2016; 173: 446-458
        • Nettekoven M.
        • et al.
        Novel triazolopyrimidine-derived cannabinoid receptor 2 agonists as potential treatment for inflammatory kidney diseases.
        ChemMedChem. 2016; 11: 179-189
        • Yrjölä S.
        • et al.
        Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
        Eur. J. Pharm. Sci. 2015; 67: 85-96
        • Riether D.
        • et al.
        Selective CB2 receptor agonists. Part 2: structure-activity relationship studies and optimization of proline-based compounds.
        Bioorg. Med. Chem. Lett. 2015; 25: 581-586
        • Bartolozzi A.
        • et al.
        Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.
        Bioorg. Med. Chem. Lett. 2015; 25: 587-592
      1. Riether D, et al. Boehringer Ingelheim International GmbH. Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles, WO2014184327A1

        • Han S.D.
        • et al.
        Discovery of APD371: identification of a highly potent and selective CB2 agonist for the treatment of chronic pain.
        ACS Med. Chem. Lett. 2017; 8: 1309-1313
        • Castro J.
        • et al.
        Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents.
        Pain. 2022; 163: e72-e86
        • Lucchesi V.
        • et al.
        CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.
        J. Med. Chem. 2014; 57: 8777-8791
        • Slavik R.
        • et al.
        Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor.
        J. Med. Chem. 2015; 58: 4266-4277
        • Saroz Y.
        • et al.
        Cannabinoid receptor 2 (CB2) signals via G-alpha-s and induces IL-6 and IL-10 cytokine secretion in human primary leukocytes.
        ACS Pharmacol. Transl. Sci. 2019; 2: 414-428
        • Oyagawa C.R.M.
        • Grimsey N.L.
        Cannabinoid receptor CB1 and CB2 interacting proteins: techniques, progress and perspectives.
        Methods Cell Biol. 2021; 166: 83-132
        • Ibsen M.S.
        • et al.
        Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: species, subtype, and agonist-dependence.
        Front. Pharmacol. 2019; 10: 350
        • Johnson M.R.
        • Melvin L.S.
        The discovery of nonclassical cannabinoid analgetics.
        in: Mechoulam R. Cannabinoids as Therapeutic Agents. CRC Press, 1986: 121-145
        • Shoemaker J.L.
        • et al.
        Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors.
        J. Pharmacol. Exp. Ther. 2005; 315: 828-838
        • Dhopeshwarkar A.
        • Mackie K.
        Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathways.
        J. Pharmacol. Exp. Ther. 2016; 358: 342-351
        • Oyagawa C.R.M.
        • et al.
        Cannabinoid receptor 2 signalling bias elicited by 2,4,6-trisubstituted 1,3,5-triazines.
        Front. Pharmacol. 2018; 9: 1202
        • Casado-Anguera V.
        • Casado V.
        Unmasking allosteric-binding sites: novel targets for GPCR drug discovery.
        Expert Opin Drug Discov. 2022; : 1-27
        • Gado F.
        • et al.
        Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.
        Future Med. Chem. 2019; 11: 2019-2037
        • Salo O.M.H.
        • et al.
        Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
        J. Med. Chem. 2005; 48: 7166-7171
        • Hurst D.P.
        • et al.
        A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor.
        J. Biol. Chem. 2010; 285: 17954-17964
        • Mnpotra J.S.
        • et al.
        Structural basis of G protein-coupled receptor-Gi protein interaction: formation of the cannabinoid CB2 receptor-Gi protein complex.
        J. Biol. Chem. 2014; 289: 20259-20272
        • Ji B.
        • et al.
        Prediction of the binding affinities and selectivity for CB1 and CB2 ligands using homology modeling, molecular docking, molecular dynamics simulations, and MM-PBSA binding free energy calculations.
        ACS Chem. Neurosci. 2020; 11: 1139-1158
        • Lynch D.L.
        • et al.
        Molecular dynamics methodologies for probing cannabinoid ligand/receptor interaction.
        Methods Enzymol. 2017; 593: 449-490
        • Xing C.
        • et al.
        Cryo-EM structure of the human cannabinoid receptor CB2-Gi signaling complex.
        Cell. 2020; 180: 645-654
        • Hua T.
        • et al.
        Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures.
        Cell. 2020; 180: 655-665
        • Lynch D.L.
        • et al.
        The nucleotide-free state of the cannabinoid CB2/Gi complex.
        Cell. 2020; 180: 603-604
        • Vann R.E.
        • et al.
        Cannabimimetic properties of ajulemic acid.
        J. Pharmacol. Exp. Ther. 2007; 320: 678-686
        • Burstein S.H.
        The cannabinoid acids, analogs and endogenous counterparts.
        Bioorg. Med. Chem. 2014; 22: 2830-2843
        • Spiera R.
        Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis.
        Arthritis & Rheumatol. 2020; 72: 1350-1360
        • Chmiel J.F.
        • et al.
        WS01.5 A phase 2 study of the safety, pharmacokinetics, and efficacy of anabasum (JBT-101) in cystic fibrosis (CF).
        J. Cyst. Fibros. 2017; 16: S2
        • Spiera R.
        • et al.
        A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
        Clin. Exp. Rheumatol. 2021; 131: 124-133
      2. Garzon A, et al. Pharmos Corp. Bicyclic CB2 cannabinoid receptor ligands, US2005.0020544A1

        • Giblin G.M.
        • et al.
        Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.
        J. Med. Chem. 2007; 50: 2597-2600
        • Ostenfeld T.
        • et al.
        A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction.
        Clin. J. Pain. 2011; 27: 668-676
        • Schou M.
        • et al.
        Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate.
        Nucl. Med. Biol. 2013; 40: 410-414
        • Kalliomaki J.
        • et al.
        Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia.
        Clin. Exp. Pharmacol. Physiol. 2013; 40: 212-218
        • Kalliomaki J.
        • et al.
        Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal.
        Scand. J. Pain. 2013; 4: 17-22
      3. Muthuppalaniappan M, et al. Glenmark Pharmaceuticals. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation, WO2006129178A1

        • Hollinshead S.P.
        • et al.
        Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
        J. Med. Chem. 2013; 56: 5722-5733
        • Lin X.
        • et al.
        Slowly signaling G protein–biased CB2 cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence.
        Mol. Pharmacol. 2018; 93: 49
        • Yacyshyn B.R.
        • et al.
        Safety, pharmacokinetics, and efficacy of olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, in a phase 2a study of patients with chronic abdominal pain associated with Crohn’s disease.
        Crohns & Colitis 360. 2021; 3otaa089
        • Chang L.
        • et al.
        OP115 efficacy and safety of olorinab, a peripherally acting, highly selective, full agonist of cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: results from a phase 2B randomized study.
        United European Gastroenterol. J. 2021; 9: 87-88
        • Postnov A.
        • et al.
        Quantification of 11C-NE40, a novel PET radioligand for CB2 receptor imaging.
        J. Nucl. Med. 2013; 54: 188
        • Spinelli F.
        • et al.
        Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor.
        J. Label. Compd. Radiopharm. 2018; 61: 299-308
        • Slavik R.
        • et al.
        Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor.
        Eur. J. Med. Chem. 2015; 92: 554-564
        • Haider A.
        • et al.
        Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue.
        Eur. J. Med. Chem. 2018; 145: 746-759
        • Sellers R.S.
        Translating mouse models: immune variation and efficacy testing.
        Toxicol. Pathol. 2017; 45: 134-145
        • Mogil J.S.
        The translatability of pain across species.
        Philos. Trans. R. Soc. Lond. B Biol. Sci. 2019; 37420190286
        • Walsh N.C.
        • et al.
        Humanized mouse models of clinical disease.
        Annu. Rev. Pathol. 2017; 12: 187-215
        • Mouraux A.
        • et al.
        Challenges and opportunities in translational pain research - an opinion paper of the working group on translational pain research of the European pain federation (EFIC).
        Eur. J. Pain (Lond. Engl.). 2021; 25: 731-756
        • Renna S.A.
        • et al.
        Human and mouse PAR4 are functionally distinct receptors: studies in novel humanized mice.
        J. Thromb. Haemost. 2022; 20: 1236-1247
        • Daley E.J.
        • et al.
        Actions of parathyroid hormone ligand analogues in humanized PTH1R knockin mice.
        Endocrinology. 2022; 163ebqac054
        • Sarott R.C.
        • et al.
        Development of high-specificity fluorescent probes to enable cannabinoid type 2 receptor studies in living cells.
        J. Am. Chem. Soc. 2020; 142: 16953-16964

      Glossary

      Affinity
      the strength of interaction between a ligand and receptor, typically quantified as the concentration of ligand that results in 50% of receptors binding ligand at equilibrium (Kd or Ki). A lesser concentration required to achieve 50% receptor binding indicates a higher affinity. Reported in this review via the parameter pKi.
      Agonist
      a receptor ligand that, upon interaction with a receptor, induces activation of one or more signalling pathways.
      Allosteric modulator
      a ligand that binds to a receptor elsewhere than the orthosteric binding site and, therefore, does not compete for binding with orthosteric ligands. By influencing receptor conformation, allosteric modulators may induce or restrict receptor activity alone or, more commonly, may positively or negatively influence the binding and/or activity of orthosteric ligands.
      Antagonist
      a receptor ligand that binds to the orthosteric binding site (and can therefore compete for binding with other orthosteric ligands) but does not itself influence receptor activity.
      Functional selectivity
      also known as biased agonism. The concept that a single receptor type can activate varying signalling patterns (may include different pathways or the same pathways to different degrees), depending on the specific ligand bound. This is produced via the stabilisation of different receptor conformations and, therefore, differential engagement with signalling effectors.
      Inverse agonist
      a receptor ligand that reduces constitutive (non-ligand-induced) activity of a receptor by stabilising an inactive conformation.
      Ligand
      molecule that has affinity for a receptor.
      Lipophilic
      tendency to combine with or dissolve in nonpolar substances such as lipids. Can be measured via logD, logP.
      logD
      partition coefficient between aqueous and organic phases at a defined pH; a measure of lipophilicity. ‘c’ for calculated.
      logP
      partition coefficient between aqueous and organic phase of a neutral compound; a measure of lipophilicity. ‘c’ for calculated.
      Orthosteric binding site
      the region in a receptor where the endogenous ligand binds. Orthosteric ligands also bind to (or have overlapping interactions with) this site/pocket and can compete for binding with endogenous ligand(s).
      pKi
      a parameter for quantifying ligand affinity. The negative log concentration of ligand that results in 50% of receptors binding ligand at equilibrium. A larger pKi indicates higher affinity. For example, a pKi of 9 is equal to a Ki of 1 nM, or 10–9 M. A pKi of 6 is equal to a Ki of 1 μM, or 10–6 M.
      Selectivity
      the relative propensity of a compound to interact with and/or produce activity via one effector (e.g., a receptor) as opposed to others. Represented in this review as the fold-difference in binding affinity between two effectors. For example, a CB2/CB1 selectivity of 1000 indicates that the concentration of ligand required to bind 50% of CB1 receptors is 1000 times greater than the same for CB2.
      Target engagement
      the ability of a molecule to interact with its intended target. Encompasses molecular interactions with the target (e.g., affinity) and access to the target in vivo (e.g., drug distribution).
      Toggle switch
      in the context of GPCRs, refers to one type of molecular switch, where one or several amino acids play a key role in receptor activation by undergoing a conformational change and therefore mediating/driving the transition of the GPCR between conformations and/or stabilising a particular conformation.
      Topological polar surface area (TPSA)
      sum of surface areas of polar atoms in a molecule. Typically reported in Å2.